Couples and dyadic psychedelic-assisted therapy is an emerging clinical model in which both partners receive the substance simultaneously, or one partner receives the substance while the other supports as a non-dosed conjoint participant. The model draws on established conjoint psychotherapies — most centrally Cognitive-Behavioral Conjugal Therapy (CBCT) for PTSD (post-traumatic stress disorder) — and on the prosocial neurobiology of MDMA to address relational distress that is often inseparable from individual symptomatology. This article is a Canadian evidence-and-pathway guide to the dyadic model: what it is, who has studied it, when it might be relevant, and — equally important — when it is not. The published evidence base is smaller and earlier than the condition-primary literature on MDMA-AT, psilocybin-assisted therapy, or ketamine-assisted therapy. Dyadic psychedelic-assisted therapy is investigational. ATMA CENA offers conventional couples therapy and is following the dyadic evidence carefully; this article frames honestly what is currently offered versus what is still in research.

Key takeaways

Dyadic psychedelic-assisted therapy is a model where both partners receive the substance simultaneously, or one partner is dosed while the other participates as a non-dosed conjoint partner. It is investigational and the evidence base is smaller than condition-primary studies.

Most-published evidence is MDMA-assisted: Wagner, Mithoefer, Mithoefer, Monson 2019 Frontiers in Psychology proposed pathways of action; Wagner et al. CBCT+MDMA hybrid for PTSD-affected couples; Wagner et al. open-label MDMA-AT for cancer patient-caregiver dyads.

MDMA has a mechanistic rationale for couples work: oxytocin release, reduced amygdala reactivity to social threat, prosocial and empathogenic effects.

Psilocybin and ketamine dyadic formats are far less studied. Group ketamine models (e.g., Roots to Thrive) exist but are distinct from a true couples dyad.

Indications where dyadic may be relevant: caregiver-patient pairs facing serious illness; PTSD with secondary partner trauma; relationship distress with co-morbid mood disorder; couples in mid-grief or major life transitions.

Intimate partner violence (IPV) screening is essential. A history of IPV is typically a contraindication for the dyadic format. Power dynamics, confidentiality, and consent require careful structuring.

Health Canada SAP applications for dyadic indications are more complex than single-patient applications; insurance coverage is essentially absent.

Not all couples are appropriate candidates. Comprehensive couples assessment precedes any dyadic consideration.

What is dyadic psychedelic-assisted therapy?

The dyadic model is an extension of two established traditions in psychotherapy: conjoint or couples-based psychotherapy (where both partners attend therapy together as the unit of treatment), and psychedelic-assisted therapy (preparation, supervised dosing, integration). Dyadic protocols recognize that many presenting problems — PTSD, end-of-life distress, complicated grief, relationship-distress comorbid with mood disorder — exist within a relational system rather than within a single individual.

Two principal structural variants exist:

Co-administration ("both-dosed") dyadic: both partners receive the substance simultaneously in the same session, with trained therapists facilitating. This is the format most directly studied in the Wagner/Monson MDMA + CBCT for PTSD work.
Asymmetric ("one-dosed") dyadic: one partner — typically the index patient — receives the substance, and the partner participates as a non-dosed conjoint support. This is closer to the Wagner cancer caregiver-patient dyad work, where the patient is dosed and the caregiver is integrated into preparation, dosing-room presence (where appropriate), and integration.

A third format — parallel individual sessions with shared integration — is sometimes informally described as "dyadic" but is closer to two parallel individual courses with conjoint integration sessions.

The dyadic evidence map

MDMA — the most-published dyadic evidence

The strongest published evidence for any dyadic psychedelic model is in MDMA-assisted therapy, concentrated in two threads of work led by Anne Wagner (Toronto) in collaboration with the Mithoefers and Candice Monson (Ryerson / Toronto Metropolitan University), and overlapping with the broader MAPS/Lykos PTSD research program.

Wagner AC, Mithoefer MC, Mithoefer AT, Monson CM. (2019). Couple Therapy With MDMA — Proposed Pathways of Action. Frontiers in Psychology, 10:1136 (PMID: 31178802). The conceptual paper laying out mechanism and protocol rationale: MDMA's oxytocin release, reduced amygdala reactivity to social threat, increased prosocial cognition, and combined with Cognitive-Behavioral Conjugal Therapy (CBCT) for PTSD (Monson and Fredman) as the structured psychotherapy scaffold. CBCT is itself an evidence-based conjoint therapy for PTSD with a meaningful trial base independent of psychedelics.
Wagner et al. (2021). First-in-couples open-label pilot of CBCT+MDMA hybrid protocol in PTSD-affected couples — small N, six couples, structured measures of both PTSD symptoms and relationship adjustment.
Wagner et al. cancer caregiver-patient dyads. Open-label MDMA-AT for adjustment-disorder-related distress in patient-caregiver pairs facing cancer; small N, structured outcomes.

The dyadic MDMA literature remains early-phase and predominantly open-label, with sample sizes in the single digits to low double digits. There are no completed phase 3 RCTs of dyadic MDMA-AT.

Psilocybin — minimal dyadic evidence

Psilocybin-assisted therapy has a much larger condition-primary RCT base (Goodwin 2022 COMP001 in TRD; Griffiths 2016 / Ross 2016 in cancer-related distress; Carhart-Harris 2021 in MDD) but the dyadic format is not the principal study design. Ross 2016 and Griffiths 2016 cancer-distress trials included caregivers in preparation/integration informally in some cases but did not study a co-administration dyadic format.

Ketamine — dyadic largely unstudied; group models distinct

There is no significant published dyadic ketamine RCT literature. Group ketamine models — most notably Roots to Thrive's group ketamine-assisted therapy program — are clinically distinct from a true couples dyad. Group models combine multiple unrelated participants into a shared dosing context with group integration; the relational unit is the cohort, not a pre-existing couple. Group and dyadic models share certain logistical and confidentiality questions but should not be conflated clinically.

Other substances

Ayahuasca and Indigenous ceremonial contexts include long traditions of community and family-based participation that lie outside the SAP/RCT framework and outside the scope of this article.

For more detail, see MDMA-Assisted Therapy in Canada, Psilocybin Therapy in Canada, Ketamine Therapy in Canada, and Group Ketamine-Assisted Therapy.

Mechanism rationale — why MDMA in particular for couples?

The published rationale (Wagner 2019) for MDMA in dyadic protocols rests on a small number of converging neurobiological observations:

Oxytocin release with MDMA administration, with hypothesized facilitation of pair-bond and attachment-relevant social cognition
Reduced amygdala reactivity to social threat cues observed on neuroimaging studies (Bedi, Carhart-Harris and colleagues)
Empathogenic / prosocial subjective effects — increased perceived closeness, reduced defensiveness, increased self-disclosure
Window for trauma processing — MDMA's reduction in fear extinction interference combined with maintained cognitive engagement enables trauma recall and reprocessing within the conjoint context

These mechanisms are plausible and supported by basic and clinical research; they do not by themselves establish efficacy or safety of the dyadic protocol in any specific population, which is what RCT evidence is required to demonstrate.

Indications where dyadic may be relevant

The published research and conceptual literature converge on a small number of clinical situations where the dyadic model has been studied or seriously proposed:

Caregiver–patient pairs in serious illness — most centrally end-of-life distress in cancer, where the patient and primary caregiver-spouse face the illness together; existential distress is shared and relational.
PTSD with partner secondary trauma — index patient with PTSD whose partner has been substantially impacted (secondary traumatic stress, accommodation behaviours, relationship distress). This is the population most directly studied in the Wagner/Monson CBCT+MDMA work.
Relationship distress with mood disorder comorbidity — depression or anxiety in one or both partners that is intertwined with relational dynamics; conventional couples therapy has proven insufficient.
Couples in mid-grief or major life transitions — pregnancy loss, sudden loss of a child, identity transitions affecting the relational unit.

These are situations where the relational system is itself a meaningful target of treatment — not simply where one partner happens to be in a relationship.

Screening — IPV, power dynamics, consent

The dyadic format introduces clinical risks that do not exist in individual psychedelic-assisted therapy. Comprehensive couples assessment is the precondition for any dyadic consideration.

Intimate partner violence (IPV) screening

A history of intimate partner violence is typically a contraindication for dyadic psychedelic-assisted therapy. This is well-established in the broader couples-therapy literature: conjoint formats can endanger a victim of IPV by exposing them to the partner in a vulnerable state, can be coercively used by perpetrators, and can compromise the safety required for honest disclosure.

Standard IPV screening instruments referenced in the conjoint-therapy literature include:

CAS (Composite Abuse Scale)
HITS (Hurt, Insulted, Threatened, Screamed)
WAST (Woman Abuse Screening Tool)
ABUSE-Q and similar partner-violence screens

These should be administered separately to each partner, in individual sessions without the other partner present, with explicit confidentiality protections for disclosure. The Wagner/Monson protocols and the broader CBCT framework treat IPV history as an exclusion criterion barring exceptional clinical circumstances.

Power dynamics within the couple

Even absent IPV, asymmetries of power — financial, immigration-status, caregiving-dependency, neurocognitive — affect the validity of consent within a dyadic protocol. The relational system that is being treated also includes the system that produces and distorts consent. Comprehensive couples assessment surfaces these dynamics before any dosing decision.

Confidentiality complexities

Dyadic therapy intrinsically alters confidentiality:

Information disclosed by one partner cannot generally be held back from the other within the conjoint format
Material that emerges under the influence of MDMA, psilocybin, or ketamine may be experienced as more vulnerable, intimate, or destabilizing than ordinary therapeutic disclosure
"No-secrets" versus "limited-secrets" policies must be articulated and consented-to in advance
Notes, recordings (where used in research), and integration content all carry shared-disclosure implications

Consent considerations

Dyadic consent is layered: each partner must consent individually to the protocol, to the substance(s), to the dyadic format, and to the specific confidentiality policy. Consent under altered states is itself a known concern in psychedelic-assisted therapy ethics; in the dyadic format, the question becomes whether interactions with one's partner under MDMA — including emotionally and sometimes physically intimate interactions — were consented to in advance. The Wagner/Monson protocols and the MAPS ethics literature treat this question explicitly; clinicians and couples should as well.

Health Canada SAP — dyadic indication complexity

For psilocybin and MDMA, Canadian access is exclusively through Health Canada's Special Access Program (SAP). Dyadic SAP applications add several layers of complexity beyond single-patient applications:

Two patient-specific applications rather than one
Both patients must independently meet SAP criteria — a substance is not approved "for the relationship," it is approved for a specific patient
The clinical justification must address each patient's individual indication and the rationale for the conjoint format
Timing and dosing coordination across two SAP approvals adds logistical complexity
Reviewer expectations for an emerging investigational model are higher; supporting evidence (Wagner 2019 onwards) is helpful but not extensive

In practice, dyadic SAP applications for MDMA in PTSD-affected couples or cancer caregiver-patient pairs are rare in Canada and would typically be advanced only by clinicians with specific training in both psychedelic-assisted therapy and conjoint/couples therapy.

For SAP background, see Psilocybin Therapy in Canada, MDMA-Assisted Therapy in Canada, and End-of-Life Distress and Psychedelic-Assisted Therapy.

Insurance coverage

Insurance coverage for dyadic psychedelic-assisted therapy is essentially absent in Canada. Conventional couples therapy is variably covered through extended health benefits (typically combined with the per-person psychotherapy maximum); dyadic psychedelic-assisted therapy adds:

Substance access cost (psilocybin, MDMA) under SAP — supply-dependent
Two simultaneous clinical fee streams for what is functionally one extended session
No Health Canada label indication for any dyadic protocol — eliminating prior-authorization-based coverage paths

Some psychotherapy hours within a dyadic protocol may be eligible for ordinary couples-therapy or psychotherapy reimbursement; the substance-administration session and substance supply are not.

For coverage background, see Insurance Coverage for Psychedelic-Assisted Therapy in Canada.

ATMA CENA's couples therapy framework — what's offered today

ATMA CENA offers conventional couples therapy as part of its psychotherapy services, and this section describes honestly what is and is not currently part of that offering.

What's offered today:

Conventional couples therapy (non-substance, evidence-based modalities)
Couples therapy as adjunct to one partner's individual psychedelic-assisted therapy course — for example, a partner's involvement in preparation and integration sessions for their spouse's individual ketamine, Spravato, or SAP psilocybin course
Coordinated care — ATMA CENA can layer alongside an existing couples therapist or family physician relationship; the existing therapist stays primary
Comprehensive couples assessment (including IPV screening, power-dynamic and confidentiality structuring) where dyadic involvement is contemplated

What is investigational and not currently a routine ATMA CENA offering:

Co-administration ("both-dosed") dyadic MDMA-AT
Co-administration dyadic psilocybin-assisted therapy
Dyadic group-ketamine formats for couples specifically

ATMA CENA is following the dyadic evidence base — particularly the Wagner/Monson CBCT+MDMA work — and will update its clinical position as Canadian regulatory and evidentiary conditions evolve. No dyadic protocol is offered as a routine clinical service today, and any consideration of dyadic SAP application would be made on a case-by-case basis with comprehensive couples assessment and the involvement of clinicians with specific dyadic-protocol training.

For services context, see how ATMA CENA coordinates care.

What the evidence does NOT say

Dyadic psychedelic-assisted therapy is not approved for any indication in Canada. It is investigational across all formats, all substances, and all populations.
The published evidence base is small. Open-label pilots and conceptual papers dominate; phase 3 RCT evidence does not exist for dyadic formats.
Dyadic is not appropriate for all couples. IPV history, severe asymmetric power dynamics, active relationship-ending dynamics, untreated bipolar or psychotic disorder in either partner, and several other clinical factors are exclusions.
MDMA's prosocial effects do not constitute relationship repair on their own. The structured CBCT (or equivalent) psychotherapy scaffold is treated in the published literature as essential; dosing without conjoint psychotherapy structure is not what was studied.
Apparent immediate closeness post-MDMA does not predict durable relational change. Integration over weeks-to-months is where outcomes are formed; one session is not the protocol.
The Roots to Thrive group ketamine model is a related but distinct format. Its evidence base does not directly transfer to the couples-dyadic question.

How ATMA CENA works with couples

For couples exploring whether psychedelic-assisted therapy is relevant to them:

Comprehensive couples assessment — including individual sessions with each partner; IPV and power-dynamic screening; mood, substance-use, and bipolar screening for both partners
Pathway clarification — most couples are appropriately served by conventional couples therapy with optional individual psychedelic-assisted therapy for one or both partners (run as parallel individual courses with shared integration), rather than by a co-administration dyadic protocol
Coordinated care layering — ATMA CENA can integrate with an existing couples therapist
Honest declination — where a dyadic format is being requested but the clinical situation is not appropriate (IPV history, untreated bipolar, severe power asymmetry, etc.), ATMA CENA will say so

Frequently asked questions

What's the difference between couples therapy and dyadic psychedelic-assisted therapy? Couples therapy is non-substance evidence-based conjoint psychotherapy. Dyadic psychedelic-assisted therapy adds a psychedelic substance — most-studied is MDMA — within a structured conjoint psychotherapy protocol. Dyadic is investigational; conventional couples therapy is well-established.

Has anyone studied couples MDMA therapy? Yes — most centrally Anne Wagner, the Mithoefers, and Candice Monson, who developed and studied the Cognitive-Behavioral Conjugal Therapy + MDMA protocol for PTSD-affected couples. Wagner et al. 2019 Frontiers in Psychology lays out the proposed mechanism. Open-label pilot data exists; no completed phase 3 RCTs.

Is dyadic psychedelic-assisted therapy approved in Canada? No. It is investigational. Access for MDMA or psilocybin would be through Health Canada's Special Access Program (SAP); dyadic SAP applications are more complex than single-patient applications.

Why MDMA in particular for couples? MDMA produces oxytocin release, reduces amygdala reactivity to social threat, and produces empathogenic / prosocial subjective effects — all relevant to conjoint trauma processing. Wagner 2019 lays out the rationale. Psilocybin and ketamine have been less studied in dyadic formats.

What about couples ketamine therapy? There is no significant published dyadic ketamine RCT literature. Group ketamine models (e.g., Roots to Thrive) exist but are not the same as a couples dyad. Some couples pursue parallel individual ketamine courses with shared integration — that is not the same model as co-administration dyadic.

Is intimate partner violence a contraindication? Yes — typically. A history of IPV is generally a contraindication for the dyadic format because conjoint contexts can endanger an IPV victim and compromise safe disclosure. Comprehensive IPV screening with both partners individually is part of the couples assessment.

How does confidentiality work in couples psychedelic-assisted therapy? Confidentiality is layered and must be structured in advance: "no-secrets" versus "limited-secrets" policies, what gets shared in integration, how disclosures under altered states are handled. This is part of comprehensive couples assessment.

Can both partners receive the substance at the same time? That is the co-administration dyadic format — most directly studied in the Wagner/Monson CBCT+MDMA work. It is investigational. The asymmetric format (one partner dosed, one supports) is more common in current clinical contexts where any conjoint involvement occurs.

Is dyadic psychedelic-assisted therapy covered by insurance? Essentially no. Conventional couples therapy may be covered by extended health benefits; the substance-administration component and SAP-supply costs are not.

What does ATMA CENA offer for couples right now? Conventional couples therapy; couples involvement (preparation/integration) in one partner's individual psychedelic-assisted therapy course; coordinated care alongside an existing couples therapist; comprehensive couples assessment. Co-administration dyadic protocols are not currently a routine ATMA CENA clinical service.

My partner has bipolar disorder — can we do dyadic therapy? Bipolar disorder in either partner is a meaningful clinical consideration; psychedelic-assisted therapy in bipolar populations is restricted to specific evidence-supported pathways (off-label ketamine with mood stabilizer coverage). See Bipolar Disorder and Psychedelic-Assisted Therapy.

We're in mid-grief together — is dyadic right for us? Possibly relevant clinically, but assessment first. Mid-grief and major life transitions are situations where the relational unit is the meaningful unit of distress; that is where the dyadic conceptual literature points. Whether the format is appropriate for a specific couple depends on the comprehensive couples assessment.

Sources

Wagner AC, Mithoefer MC, Mithoefer AT, Monson CM. (2019). Couple Therapy With MDMA — Proposed Pathways of Action. Frontiers in Psychology, 10:1136. PMID: 31178802.
Wagner AC, Liebman RE, Mithoefer AT, Mithoefer MC, Monson CM. (2021). Relational and growth outcomes following couples therapy with MDMA for PTSD. Frontiers in Psychiatry / open-label pilot reporting.
Monson CM, Fredman SJ. (2012). Cognitive-Behavioral Conjugal Therapy for PTSD: Harnessing the Healing Power of Relationships. Guilford Press.
Monson CM, Fredman SJ, Macdonald A, et al. (2012). Effect of cognitive-behavioral couple therapy for PTSD: a randomized controlled trial. JAMA, 308(7):700-9. PMID: 22893167.
Mitchell JM, Bogenschutz M, Lilienstein A, et al. (2021). MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study (MAPP1). Nature Medicine, 27(6):1025-1033. PMID: 33972795.
Mithoefer MC, Feduccia AA, Jerome L, et al. (2019). MDMA-assisted psychotherapy for treatment of PTSD: study design and rationale for phase 3 trials. Psychopharmacology, 236(9):2735-2745. PMID: 31065731.
Bedi G, Hyman D, de Wit H. (2010). Is ecstasy an "empathogen"? Effects of MDMA on prosocial feelings and identification of emotional states in others. Biol Psychiatry, 68(12):1134-40. PMID: 20947066.
Dumont GJ, Sweep FC, van der Steen R, et al. (2009). Increased oxytocin concentrations and prosocial feelings in humans after ecstasy (MDMA) administration. Soc Neurosci, 4(4):359-66. PMID: 19562632.
Hegarty K, Sheehan M, Schonfeld C. (1999). A multidimensional definition of partner abuse: development and preliminary validation of the Composite Abuse Scale (CAS). J Fam Violence, 14:399-415.
Sherin KM, Sinacore JM, Li XQ, Zitter RE, Shakil A. (1998). HITS: a short domestic violence screening tool for use in a family practice setting. Fam Med, 30(7):508-12. PMID: 9669164.
Roots to Thrive — Group Ketamine-Assisted Therapy program publications and program description: https://rootstothrive.com/
Health Canada — Special Access Program: https://www.canada.ca/en/health-canada/services/drugs-health-products/special-access.html
Health Canada — SAP psychedelic-assisted psychotherapy announcement: https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/announcements/requests-special-access-program-psychedelic-assisted-psychotherapy.html

Last updated: 2026-05-06

Couples and Dyadic Psychedelic-Assisted Therapy in Canada

Access and legality vary by jurisdiction